Evidence map›Paper›PMID 30225613›Full record

ReviewCurrent atherosclerosis reports2018

How Heart Rate Should Be Controlled in Patients with Atherosclerosis and Heart Failure.

Rose Mary Ferreira Lisboa da Silva, Anaisa Silva Roever Borges, Nilson Penha Silva, Elmiro Santos Resende, Gary Tse, Tong Liu, Leonardo Roever, Giuseppe Biondi-Zoccai

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current atherosclerosis reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 3 countries.

Rose Mary Ferreira Lisboa da SilvaDepartment of Internal Medicine, Faculty of Medicine, Federal University of Minas Gerais, Belo Horizonte, Brazil. roselisboa@uol.com.br.
Anaisa Silva Roever BorgesMaster Institute of Education President Antonio Carlos, IMEPAC, Araguari, Brazil.
Nilson Penha SilvaDepartment of Clinical Research, Federal University of Uberlandia, Uberlândia, Brazil.
Elmiro Santos ResendeDepartment of Clinical Research, Federal University of Uberlandia, Uberlândia, Brazil.
Gary TseDepartment of Medicine and Therapeutics, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, China.
Tong LiuTianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, the Second Hospital of Tianjin Medical University, Tianjin, China.
Leonardo RoeverDepartment of Clinical Research, Federal University of Uberlandia, Uberlândia, Brazil.
Giuseppe Biondi-ZoccaiDepartment of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy.
Universidade Federal de Uberlândia · BRChinese University of Hong Kong · CNIstituto Neurologico Mediterraneo · ITTianjin Medical University · CNUniversidade Federal de Minas Gerais · BRUniversidade Presidente Antônio Carlos · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewResting heart rate is an independent risk factor for all-cause and cardiovascular mortality in patients with heart failure. The main objectives are to discuss the prognosis of heart rate, its association with coronary atherosclerosis, and the modalities of control of the heart rate in sinus rhythm and in the rhythm of atrial fibrillation in patients with chronic heart failure. RECENT

findingsAs a therapeutic option for control heart rate, medications such as beta-blockers, digoxin, and finally ivabradine have been studied. Non-dihydropyridine calcium channel blockers are contraindicated in patients with heart failure and reduced ejection fraction. The influence of the magnitude of heart rate reduction and beta-blocker dose on morbidity and mortality will be discussed. Regarding the patients with heart failure and atrial fibrillation, there are different findings in heart rate control with the use of a beta-blocker. Patients eligible for ivabradine have clinical benefits and increased ejection fraction. Vagal nerve stimulation has low efficacy for the control of heart rate. Complementary therapies such as tai chi and yoga showed no effect on heart rate. In this review, we discuss the main therapeutic options for the control of heart rate in patients with atherosclerosis and heart failure. More research is needed to examine the effects of therapeutic options for heart rate control in different population types, as well as their effects on clinical outcomes and impact on morbidity and mortality.

Indexed as

Cardiovascular AgentsHeart FailureAtrial FibrillationCoronary Artery DiseaseHeart RateHumansPrognosisCardiovascular AgentsBeta-blockerHeart rateIvabradineMortalitySystolic heart failure

Identifiers

PMID30225613
OpenAlexW2890860135

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.